|Calculated MW||90/120 KDa|
|Other Names||Progesterone receptor, PR, Nuclear receptor subfamily 3 group C member 3, PGR, NR3C3|
|Target/Specificity||Synthetic phospho-peptide corresponding to amino acid residues surrounding Ser190 conjugated to KLH.|
|Format||Prepared by affinity purification using a protein G column.|
|Antibody Specificity||Specific for the ~90k PR-A isoform and the ~120k PR-B isoformphosphorylated at Ser190. Immunolabeling is blocked by the phosphopeptide used as antigenbut not by the corresponding dephosphopeptide.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Phospho-Ser190 Progesterone Receptor Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
There is accumulating evidence to suggest that progesterone plays an essential role in the regulation of growth and differentiation of mammary glands and thus may play a key role in breast cancer (Edwards, 2005). The biological response to progesterone is mediated by two distinct forms of the human progesterone receptor (PR-A and PR-B forms). In most cell contexts, the B form functions as a transcriptional activator, whereas the A form functions as a transcriptional inhibitor of steroid hormones (Attia et al., 2000; Lin et al., 2003). Recently it has been demonstrated that there is differential hormone dependent regulation of the phosphorylation of the A and B forms of the receptor (Clemm et al., 2000) . Treatment of T47D breast cancer cells with progestin agonist increases the phosphorylation of Ser 190 and Ser 294 with different kinetics. These phosphorylation events may differentially affect the transcriptional activity of the receptor.
Attia GR, Zeitoun K, Edwards D, Johns A, Carr BR, Bulun SE (2000) Progesterone receptor isoform A but not B is expressed in
endometriosis. J Clin Endocrinol Metab 85:2897-2902.
Clemm DL, Sherman L, Boonyara
tanakornkit V, Schrader WT, Weigel NL, Edwa
rds DP (2000) Differential hormone-dependent
phosphorylation of progesterone receptor A and B forms reveal
ed by a phosphoserine site-specific monoclonal antibody.
Mol Endocrinol 14:52-65.
Edwards DP (2005) Regulation of signal transduction pathwa
ys by estrogen and progesterone. Annu Rev Physiol 67:335-376.
Lin VC, Woon CT, Aw SE, Guo C (2003) Distinct molecular path
ways mediate progesterone-induced growth inhibition and
focal adhesion. Endocrinology 144:5650-5657
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.